WTA adopts mandatory genetic sex testing for all women’s‑tour players
The Women’s Tennis Association (WTA) announced a new eligibility policy that will require every player on the women’s tour to undergo a one‑time genetic test for the SRY gene, which indicates biological male sex. The test can be performed via a cheek swab, blood or saliva sample and will take effect on 21 July 2026. A negative result clears a player to compete, while a positive result triggers further medical assessment before eligibility is confirmed. Players who refuse the test may face disciplinary action, including possible suspension.
The policy replaces the previous rule that allowed transgender women to compete if they maintained testosterone levels below 2.5 nmol/L for two years. The WTA says the change aims to preserve fair competition and aligns with recent International Olympic Committee (IOC) guidelines and similar measures adopted by World Athletics and World Boxing ahead of the 2028 Los Angeles Olympics. The association emphasized that the rule is intended to be applied respectfully and with dignity, noting that no known transgender women are currently active on the professional tour.